Injective CEO Engages White House, Regulators on On-Chain Finance
Injective CEO Eric Chen recently held discussions with officials from the White House, the Securities and Exchange Commission (SEC), and the Commodity Futures Trading Commission (CFTC) concerning the advancement of regulated on-chain finance within the United States.
The meetings, which occurred in October 2026, saw Chen accompanied by other members of Injective’s leadership team. The company has not yet revealed the specific outcomes of these engagements.
The core of the discussions revolved around two interconnected themes: regulated on-chain finance and the tokenization of real-world assets (RWAs).
Injective brought a unique qualification to these discussions, a credential that distinguishes it from many other cryptocurrency projects. In August 2026, the SEC officially registered Injective as a transfer agent.
Transfer agents serve as the often-overlooked record-keepers in traditional finance, maintaining the definitive ledgers that track security ownership. This designation allows Injective to manage ownership records for tokenized securities, a crucial component that institutional investors require before committing significant capital to on-chain activities.
The company also highlighted its network’s operational activity, reporting over $1 billion in tokenized RWA value on-chain. Injective further stated that its cumulative RWA perpetual volume has surpassed $5.3 billion, encompassing a range of asset classes including equities and commodities.
In 2025, Injective had previously submitted a proposal advocating for a time-based exemption for decentralized finance (DeFi) projects. The objective was to provide early-stage DeFi protocols with a development window before being subjected to the full scope of securities regulations.
Regulatory Shifts and Injective’s Position
A significant development occurred in September 2026 when the SEC introduced its Innovation Exemption. This move was interpreted as a signal of the regulator’s increasing openness to accommodating new financial technologies.
Injective has also made strides in the derivatives sector. The listing of INJ futures on CFTC-regulated U.S. markets in late 2026 places the token among a select group of digital assets supporting regulated derivatives trading in the country.
The company has also leveraged its own events to engage with lawmakers. The Injective Summit has previously hosted discussions involving bipartisan members of Congress.
When viewed chronologically, these events suggest a deliberate strategy: a policy proposal in 2025, followed by transfer agent registration in August 2026, and culminating in regulated futures listings and high-level meetings with the White House, SEC, and CFTC later that same year.
While Injective has not announced any new approvals stemming from these recent meetings, the establishment of a regulated framework could potentially reduce the perceived risk associated with DeFi markets for investors and traders. This is particularly relevant for institutional players, who typically prioritize clear legal standing.
However, significant risks remain. Regulatory momentum can falter or reverse, and meetings alone do not guarantee favorable policy outcomes. Furthermore, the on-chain figures cited by Injective, including the $1 billion in tokenized RWA value and over $5.3 billion in cumulative perpetual volume, are self-reported by the company.
The SEC’s Innovation Exemption represents a notable shift in regulatory sentiment. The practical impact on DeFi operations will ultimately depend on the specific projects that qualify for this exemption and the terms under which they do so.
